Just to be clear: The patient numbers cited in #msg-54314266 are for genotype-1 only. The HCV commercial opportunity for non-genotype-1 patients is quite large in its own right relative to the valuation of many smaller biotech companies, but is not as material for such Big Pharma as Roche, MRK, JNJ, and BMY.
Market Data 
Markets 
AI
